MedTrace Logo

Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis

NCT02988778 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2019-10-09

No results posted yet for this study

Summary

This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Budesonid 50mcg (Noex)

Suspention to nasal use, 2 atomization in each nostril during the morning and at night.

DRUG

Budesonid 50mcg (Busonid)

Suspention to nasal use, 2 atomization in each nostril during the morning and at night.

Sponsors & Collaborators

  • Eurofarma Laboratorios S.A.

    lead INDUSTRY

Principal Investigators

  • Mauro Acir Crippa Junior, MD · Allergisa Pesquisa Dermato-Cosmetica LTDA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2019-10-08
Completion
2019-10-08

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02988778 on ClinicalTrials.gov